Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for hidden chemical signatures to catch head and neck cancers early

NCT ID NCT07377084

Knowledge-focused Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find a unique chemical pattern (metabolomic signature) in blood, urine, and tumor samples from 250 people with upper aerodigestive tract cancers. By analyzing these samples before and after treatment, researchers hope to improve early detection, predict treatment response, and spot recurrences sooner. No extra tests or risks are involved—only samples already collected during standard care are used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2020

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes patients managed for a suspected upper aerodigestive tract tumor undergoing ENT panendoscopy with biopsies, with final inclusion limited to patients with histologically confirmed squamous cell carcinoma of the upper aerodigestive tract.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically proven squamous cell carcinoma of the upper aerodigestive tract (oral cavity, oropharynx, larynx, and hypopharynx), stage T1-4, N0-3, M0, untreated. * Curative treatment planned at CAL. * Patient who has voluntarily consented to the use of their data and signed a non-opposition form for the use of their biological and tumor samples. Exclusion Criteria: * Metastatic patient (M1). * No curative treatment possible. * History of cancer (other than basal cell carcinoma) in the last 5 years. * Tumor size deemed insufficient according to the assessment of the ENT surgeon. * Patient refusal to allow the use of their biological and tumor samples for research. * Vulnerable persons are defined in articles L1121-5 to -8: * Pregnant women, women in labor, and nursing mothers, individuals deprived of liberty by a judicial or administrative decision, individuals hospitalized without consent under articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of article L. 1121-8, * And individuals admitted to a health or social establishment for purposes other than research, * Adults under legal protection or unable to express their non-opposition.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Squamous cell carcinoma of the upper aerodigestive tract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma upper aerodigestive tract neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Upper aerodigestivetract cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Antoine Lacassagne

    RECRUITING

    Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.